Albireo Pharma Sells Bylvay-Associated PRV For $105M

by Vandana Singh, Benzinga Editor

September 7, 2021 11:04 AM | 1 min read |

Albireo Pharma Inc ALBO has agreed to sell its Priority Review Voucher (PRV) for $105 million.
The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
Related Content: Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US.
The net sales proceeds expected from the transaction are in addition to the $186.3 million in cash, cash equivalents, and short-term investments Albireo reported as of June 30, 2021.
Price Action: ALBO shares are down 0.24% at $29.60 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Asset Sales Small Cap General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.